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Abstract
Introduction: We sought to examine the association between livelihood security and adherence to antiretroviral therapy
(ARVs) in low- and middle-income countries (LIMC).
Methods: Performing a systematic review, we searched, independently and in duplicate, 7 electronic databases and 2
conference websites for quantitative surveys that examined the association between indicators of livelihood security and
adherence to ARVs in LIMC between 2000–2010. Criteria for relevance were applied to complete papers (quantitative study
with estimates of associations) and quality assessment was conducted on those deemed relevant. We performed three
regressions to measure the association between each type of livelihood and adherence.
Results: Twenty original studies and 6 conference abstracts were included, the majority from Africa (n=16). Seventeen
studies and 3 conference abstracts were cross-sectional and 3 studies and 3 abstracts were prospective clinical cohort
studies, with considerable variation in quality for studies of each design type. Among the diverse populations represented,
we observed considerable variation in associations between measurements of livelihood indicators and increasingly
accepted adherence measures, irrespective of study design or quality. A financial capital indicator, financial constraints/
payment for ARV medication, was more commonly associated with non-adherence (3/5 studies). A human capital indicator,
educational level, was most commonly associated with adherence (11/20 studies).
Discussion: Additional better quality research examining livelihood security is required to inform provision of optimal
supports for adherence and mitigation of the impacts of HIV/AIDS.
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Introduction
The HIV/AIDS epidemic has taken a particular toll on low-
and middle-income countries (LIMC), with sub-Saharan Africa
heavily affected by both disease and poverty. Among the many
challenges faced by clinicians and AIDS organizations are
maintaining health in the face of poverty that may preclude
access to food and medication adherence [1]. Although several
development initiatives have been established by different
AIDS organizations, such as micro-finance and support groups,
little is understood about the impact of livelihood security
and its eventual impact on long-term patient status, including
mortality.
Livelihood is closely linked to socio-economic status (SES), a
term often used to reflect an individual’s access to resources such
as food, potable water, health facilities, educational opportunities,
and housing [1,2]. Assets include the types of capital that can be
used directly or indirectly to generate livelihoods and reflect
natural (e.g., land, water), physical (e.g., infrastructure, roads),
financial (e.g., money, savings, income), human (e.g., knowledge,
education, ability to work), and social (e.g., networks, kin,
membership in a group) forms [3]. A livelihood approach, as a
framework, explores how individuals, households, or communities
behave under specific conditions, analyzing their ability to cope
and adapt in response to external shocks such as drought or civil
strife [4,5].
In the context of HIV/AIDS, there has been growing
recognition that the various aspects of livelihoods that increase
risk of illness and death need to be identified [1]. Limited
livelihood security can lead to engaging in risky behaviours that
increase HIV incidence [5]. Among those receiving ARVs, limited
livelihoods can reduce adherence, create adverse gastrointestinal
and other adverse events due to poor diets, and lead to disrupted
medication supplies [1,5–7].
Highly active antiretroviral therapy (HAART) provides the
hope that people living with HIV/AIDS (PLWHA) can now live
longer [8,9] and more productive lives. Nevertheless, as of 2008,
only 42% of clinically eligible individuals in LIMC were receiving
treatment [10], despite the fact that treatment has been recognized
as an essential tool for mitigating the impacts of HIV on affected
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sustained adherence, critical for viral suppression and the
prevention of resistance, disease progression, and death [12,13].
Unfortunately, adherence remains a challenge for many [14–16],
given obstacles such as dosing schedules, dietary requirements, and
adverse effects [15,17].
Since the rapid scale-up of ARVs in resource-limited settings,
numerous studies have focused on treatment adherence
[14,15,18]. In 2006, we previously reviewed facilitators and
barriers to adherence in developed and developing nations, some
of which were livelihood-related (e.g., cost, available social
support). However, our review was limited in its ability to directly
measure the associations between identified factors and adherence
levels [15]. There remain important gaps in our understanding of
the relationship between livelihood security and adherence to
ARVs, specifically in the context of treatment sustenance. The
objective of our review is to evaluate the adherence literature
specifically focused on the role of livelihood security on adherence
to ARVs in LMIC.
Methods
Inclusion Criteria
We aimed to include all observational studies that examined the
association between financial, human, and social capital, as
important indicators of livelihood security, and adherence to
ARVs in LMIC settings.
Ethics
Ethical approval was not sought for this systematic review as
only published data was included. Furthermore, no personal
identifiers from patients described in included studies were
included. Therefore, written consent from such patients was
neither sought nor needed.
Search Strategy
We searched the following databases: AMED (inception to
January 2010), Campbell Collaboration (inception to January
2010), CinAhl (inception to January 2010), CAB Abstracts
(inception to January 2010), Cochrane Library (inception to
January 2010), Embase (inception to January 2010), and PubMed
via Medline (inception to January 2010). Conference abstracts
from the International AIDS Society conferences (inception to
2009) and Conferences on Retroviruses and Opportunistic
Infections (inception to 2009) were also sought.
Our search strategies combined terms that represented
livelihood security and HIV. An initial scan of the literature
noted that the majority of potentially relevant studies focused on
financial, human, and/or social forms of capital. While the role of
natural and physical capital was referred to in the qualitative
literature, their association with adherence were infrequently
estimated. Therefore, in the present study, we focused solely on
financial, human, and social types of capital. Using the UK
Department of International Development (DFID) Sustainable
Livelihood Framework as a guideline [19], financial capital in the
present study denotes access to financial resources; human capital
encompasses skills, knowledge, the ability to work, and nutritional
factors; and social capital refers to formal and informal social
relationships.
As we were interested in the interaction between adherence and
antiretroviral therapy, HIV and livelihoods, our search strategy
combined terms representing ‘‘HIV OR AIDS’’ AND ‘‘adherence
to antiretroviral therapy’’ AND ‘‘financial capital OR human
capital OR social capital’’. We supplemented this search by
reviewing the bibliographies of key papers. As the PRISMA
Guidelines for Meta-Analyses and MOOSE guidelines for
Systematic Reviews of Observational Studies [20] suggest that
observational studies are often not indexed well, we did not limit
our search by study design.
Study selection
BR and DCC independently reviewed the abstracts. Initially,
eligible studies met the following criteria: (1) reported an original
research study; (2) measured adherence to antiretroviral therapy;
(3) contained content addressing the association between social,
human, or financial capital and adherence to antiretroviral
therapy; and (4) was set in a low-income or middle-income
country as defined by the World Bank Country Classification [21].
The relevant qualitative studies, though useful with discussions on
the contribution of livelihood factors, could not contribute
information on the estimate of the association between the
livelihood measures of interest and adherence, and, as a result,
were excluded.
Quality Assessment
We extracted data on the quality of included studies using
criteria consolidated from existing critical appraisal sources
[14,22,23]. As many studies were clinical case series, with
populations of patients being asked additional questions during
regular visits, some criteria relevant for more traditional
population surveys were not helpful for our assessment (e.g.,
representativeness of population, use of random selection). For
longitudinal studies we added criteria with respect to follow-up:
1) the proportion followed at each stage of the study was
described-(e.g., numbers potentially eligible, examined for eligi-
bility, confirmed eligible, included in the study, completing follow-
up, and analyzed) and 2) participants reasons for non-participation
at each follow-up were presented [23–25]. Conference abstracts
usually did not contain sufficient information upon which to
conduct quality assessments. Given the limited number of
available studies and our interest in exploring the association of
livelihood and adherence in a range of LMIC, we chose not to
exclude any study based on quality.
Data Abstraction
When the full-text of an abstract was not available or when
information was not available in the full-text paper, we contacted
the study authors for additional information. BR initially appraised
quality and content and abstracted relevant data. DCC acted as a
secondary reviewer. When disagreement occurred we reached
consensus through discussion. The reviewers discussed the studies
including characterization of different livelihood measures report-
ed, the strengths of different adherence measures, and the patterns
of findings encountered. In addition to descriptive material, we
abstracted data on prevalence e.g. of other livelihood factors
associated with adherence, and the types and magnitudes of
associations e.g. of education with adherence, reported in each
study.
Quantitative Data Synthesis
Studies were organized and sorted by year of publication, by
study design, by sample size, by response rate, and by the
livelihood measures examined. The prevalence of various
livelihood measures were determined and the proportion of
participants reporting each livelihood factor was also captured
from individual studies. Patterns across studies were then
examined with respect to the estimates of the given associations
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consistently measured the same independent (i.e. livelihood)
factors and dependent variable (i.e. adherence) we chose to run
three separate meta-regressions for each type of livelihood
measure (financial, human, social) as a predictor to determine if
there were individual effects on adherence levels. Analyses were
performed in STATA. A p-value of less than 0.05 was considered
statistically significant.
Results
Study Selection and Characteristics
The initial literature search produced 1209 papers and 469
conference titles and abstracts. There was near perfect agreement
between BR and DCC on choosing the potentially relevant 42
papers and 21 abstracts from this larger set. Of these, 20 papers
[26–45] and 6 conference abstracts [46–51] were judged relevant
for our review (See Figure 1). There was perfect agreement on the
final papers and abstracts selected (kappa=1). All were published
in English. The majority of included papers initially were
identified in PubMed via Medline (n=15, 75%) [26–30,32,33,
35,37–42,45]. Of the remaining 5 papers, 4 were from Embase
[31,34,36,43] and one was identified from the CAB Abstracts
database [44]. All included abstracts were identified through the
International AIDS Society conference abstract database.
All included papers and abstracts employed a quantitative
methodology and used structured questionnaires (n=8)
[26,35,37,42,45,48,50,51] or structured interviews (n=18) [27–
34,36,38–41,43,44,46,47]. Seventeen of the papers [26–42] and 3
of the conference abstracts [46–48] were cross-sectional studies
and 3 papers [43–45] and 3 abstracts [49–51] were longitudinal
studies, following up patients over time. Almost all studies (n=19)
used logistic regression analysis to measure the association between
livelihoods and adherence. One study [43] used Cox’s propor-
tional hazards to assess the relative hazard of non-adherence.
Although detailed information on the nature of statistical analysis
was poorly described, all abstracts reported conducting multivar-
iable analysis.
Figure 1. Flow Chart of Studies Included in Review.
doi:10.1371/journal.pone.0018948.g001
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Tables 1 and 2 display the quality criteria results. There was no
improvement in quality over time and no studies reported
contacting non-responders. The proportion of studies meeting
our quality criteria ranged from 0–100%.
All cross-sectional studies adequately described the setting,
variables included, and data measurement sources, and provided
descriptive characteristics of included participants. Ten studies
(58.9%) noted use of a previously validated survey [28–32,34–
38,41], but few studies reported pre-testing their survey instrument
(n=5, 29.4%) [30,31,35,38,41]. Nine (52.9%) studies reported
both unadjusted and adjusted estimates [27,28,33–38,40] and
eight (47.1%) justified the inclusion of any covariates
[27,28,33,34,36–38,40] (no studies reported stratification so we
only assessed the use of adjustment).
All longitudinal studies described the study setting, the
populations sampled, the variables and data measurement sources
used, provided information on informed consent, provided
descriptive characteristics of participants, and provided data on
outcome events and summary measures. One study used a
previously validated questionnaire [44] yet none of the two studies
conducting interviews provided details on whether the interviewer
had been trained. Only one study provided detail on the follow-up
of participants and the reasons for losses-to-follow-up [45]. Two
studies (66.7%) reported unadjusted and adjusted estimates and
also justified their inclusion of covariates [43,45].
Settings and Populations (Tables 3 and 4)
Sixteen studies (13 papers, 3 abstracts) were conducted in Africa
[26–32,35,39,41,44,45,46,49–51]. Seven studies (6 papers, 1
abstract) were conducted in Central and South America
[33,34,37,38,42,43,48], with the majority in Brazil
[33,34,37,43,48]. Two studies (1 paper, 1 abstract) [36,47] were
conducted in India and 1 study in China [40]. Since the most
recent systematic review which examined factors affecting
adherence [15], eleven cross-sectional (64.7%) [26,27,29,31,35–
37,39,40,42] and 2 longitudinal studies (66.7%) have been
published [44,51].
Included studies reflect a diverse range of settings and study
populations. Studies were conducted primarily in public, teaching,
or referral hospitals (n=9), public outpatient or community-based
clinics (n=10), and specialist/HIV clinics or treatment centres
(n=6), although private clinics (n=3) and a workplace ARV
programme (n=1) were also reported. The proportion of women
included in cross-sectional studies ranged from 1–77% (median
51.5%) and between 35–64% (median 43%) in longitudinal
studies. The median age was 37.9 and 35 for participants in cross-
sectional and longitudinal studies respectively. The response rate
was unknown for 4 cross-sectional papers [28,32,35,37] and all
conference abstracts.
Adherence Threshold Measurements
Twenty-two studies (84.6%) assessed adherence using patient-
reported adherence levels over a specified period. One study used
pharmacy claims and three used a combination of patient and
clinician/provider assessment. Twelve papers [28–34,40–
42,43,44] and 4 abstracts [47–50] defined adherence as greater
or equal than 95% during the measurement period, which ranged
from 2 days to 6 months. Five studies [26,35,38,39,51] defined
adherence as being 100% during the measurement period. Three
studies [36,37,45] assessed adherence as greater than 90% over
the measurement period. Median adherence proportions in cross-
sectional studies were 74.3% (Range 25–88%) for papers alone
and 73.6% when the three conference abstracts were added. While
the median adherence levels among the 3 longitudinal studies were
58.1%, it increased to 70% when the three conference abstracts
were added. Overall range differed little from the cross-sectional
studies (36.9–88%).
Financial, Human, and Social Capital Factors Affecting
Adherence: (Tables 5–9)
Financial Capital. Five studies, 4 cross-sectional [27,35,36,
41] and 1 longitudinal [45], measured the association between
financial constraints/ability to pay for treatment and adherence.
Two reported lower levels of adherence associated with increasing
financial difficulties [27,41]. One study reported that the need to
sacrifice health to pay for other resources such as housing was
associated with non-adherence (Odds Ratio (OR): 19.8, 95%
Confidence Intervals (CI): 3.1–122.7) [35]. One study reported
that non-adherence was associated with having access to free
treatment (OR: 4.05, 95% CI: 1.42–11.54) [36] while another
reported that the association between financial constraints and
adherence was not-significant when examined over time [45].
Five cross-sectional [28,32,34,37,39] and 2 longitudinal [43,45]
studies examined the association between household income and
adherence, 4 of which demonstrated a non-significant association
[32,34,39,45]. One study reported an increase in non-adherence
associated with a monthly income of ,$50 US (Adjusted OR
(AOR): 2.77, 95% CI: 1.64–4.67) [28] while one cross-sectional
and one longitudinal study reported that adherence was associated
with an increase in household (AOR: 2.33, 95% CI: 1.17–4.66)
[37] or individual income (Relative Hazard (RH): 1.61, 95% CI:
1.08–2.39) [43].
Five studies (4 cross-sectional [29,35,38,39], 1 longitudinal [49])
examined how distance from the clinic and the ability to pay for
transport impacted adherence. One large study showed a non-
significant association [29]. One study demonstrated that living
more than 20 km away was positively associated with better
adherence [39], while two studies demonstrated a negative
association, with non-adherence increasing with distance (OR:
1.2, 95% CI 1.0–1.5) [35] or difficulty finding transport (AOR:
6.3, 95% CI: 1.5–26.9) [38].
There was a statistically significant positive association demon-
strated between overall financial livelihood and adherence
proportions (exponentiated beta coefficient= 1.53, 95% CI:
1.03–2.29, p=0.04).
Human Capital. Fifteen cross-sectional [28,30–34,36,37,39–
42,46–48], and five longitudinal [43,44,49–51] studies examined
the association between education and adherence. One study
examined HIV knowledge and reported that increasing education
and knowledge about HIV was associated with adherence (AOR:
3.20, 95% CI: 1.24–8.26) [40]. Six cross-sectional [30,33,34,36,
46,47] and four longitudinal studies [43,44,50,51] reported a
positive association between education and adherence. Two cross-
sectional studies reported a negative association: one reporting that
a formal education was associated with non-adherence [39] and
another reporting higher levels of adherence among individuals
who had not completed secondary school compared to those who
had (OR: 3.87, 1.21–12.40) [41].
Nine studies, seven cross-sectional [26,28,31,32,36,42,48] and
two longitudinal [43,49], examined the association with employ-
ment status. Of these, one cross-sectional [26] and one
longitudinal [43] study reported a positive and significant
association between employment and adherence.
Three studies, 2 cross-sectional [31,38] and one longitudinal
[45], measured the association with food-related restrictions. One
study reported that adherence was positively associated with eating
well [31] while another demonstrated that non-adherence was
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(OR: 6.7, 95% CI: 1.3–35.7) [38].
No statistically significant association between human capital
and adherence was found (exponentiated beta coefficient=1.04,
95% CI: 0.71–1.53, p=0.81).
Social Capital. Four studies (3 cross-sectional [28,39,41], 1
longitudinal [49]) examined the role of marital status: one study
demonstrated that being single was positively associated with
adherence (AOR: 2.93, 95% CI: 1.32–6.5) [28] while another
demonstrated that being single was negatively associated with
adherence [39]. Being married was positively associated with
adherence in one longitudinal study [49].
One cross-sectional (OR: 2.36, 95% CI: 1.08–5.15) [26] and 1
longitudinal study (AOR: 1.19, p=0.0352) [51] reported a positive
association between household size, specifically the number of
children, and adherence.
Three studies, 3 cross-sectional [28,40,48] and one longitudinal
[43]), examined the role of social support: One study found that
using support networks as reminder tools was positively associated
with adherence (AOR: 3.49, 95% CI: 1.36–8.96) [40]. A
longitudinal study reported that not participating in any religious
activities was associated with non-adherence (Adjusted RH (ARH):
2.27, 95% CI: 1.58–3.25) [43].
Fear of stigma and disclosure of HIV status was examined in 5
cross-sectional studies [29,32,35,41,47]. Two studies reported that
stigma was negatively associated with adherence to ARVs [32,47].
Overall social livelihood and adherence were positively
associated but not significant for this set of studies (exponentiated
beta coefficient: 1.79, 95% CI: 0.63–5.08, p=0.21).
Patient-report reasons for missing doses/non-adherence
Ten cross-sectional studies [28,30–32,36,38–42] and two
longitudinal studies [44,50] reported additional patient-identified
barriers to treatment adherence (i.e., reasons for missing doses).
Reported barriers included: financial difficulties (n=7)
[28,30,36,39,41,44,50], being or travelling away from home
(n=7) [28,31,32,36,38,39,41], fear of stigma (n=3) [32,40,41],
the need to participate in social activities (n=2) [40,42], food
restrictions (n=2) [40,42], inadequate family support (n=1) [44]
and occupational factors (n=1) [44].
Discussion
The diversity of studies included in this review and the lack of
consistency between them suggests that the literature on livelihood
and HIV treatment outcomes is still in its infancy. Studies were
conducted in numerous settings and the measurement tools used
to assess and define both livelihood factors and adherence varied
substantially. Adherence proportions ranged from 25% to 88%
and were tested for associations with ten different livelihood factors
related to financial, human, or social capital.
Education level was the most commonly measured livelihood
factor. While almost all studies indicated that a higher level of
education was associated with adherence, two studies reported a
negative association [39,41]. Higher levels of education have
previously been associated with increased risky behavior and risks
of HIV infection [52]. The reasons for this remain unclear.
Talam et al. (2008) argue that better educated patients may be
too busy with their professional activities to take their pills
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PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e18948Table 3. Characteristics of included cross-sectional papers [n=17, (26–42)] and conference abstracts [n=3, (46–48)].
Author Yr Country N Setting
Female
(%)
Median
Age, y
Response
Rate Assessor
Adherence, %
threshold for
measurement
Adherence
Proportion (%)
Aboubacrine 2007 Mali, Burkina
Faso
270 Public hospital,
community
based clinics
65 36–40
(median
range)
100 patient less than 100%, no.
doses missed in past
7 days
58.5
Boyer 2009 Cameroon 532 Public hospital 70.9 mean
(SD): 38 (9)
83.9 patient high, moderate, low
score in past 4 days
56.6
Byakika-Tusiime 2005 Uganda 304 ARV delivery
centres
53 39 unknown patient $95%, No. doses
taken/no.prescribed
in last 3 days
68
Carlucci 2008 Zambia 409 Rural mission
hospital
63 39 (32–47) 78.2 patient $95%, No. doses
taken/no. doses
prescribed for total time
83.7
Iliyasu 2005 Nigeria 263 Teaching
hospital
34 36.2 (3.3) 94 patient $95%, based on
previous 7 days
54
Malangu 2008 South Africa 180 Hospital 68.8 36.7 (8.1) 63.2 patient $95%, No. doses
taken/no. doses in
past 7 days
57.2
Nachega 2004 South Africa 66 public
outpatient
clinic
77 36.1 (10.1) Unknown patient $95%, No. doses
taken/no. doses in
past 30 days
88
Nemes 2004 Brazil 1972 Health service
sites
38 39.3 97 patient $95%, No. doses
taken/no. doses in
past 3 days
75.1
Pinheiro 2002 Brazil 195 Publicly
funded
specialist clinic
39 35 (17–67) 84 patient $95%, No. doses
taken/no. doses
prescribed in
past 2 days
56.9
Ramadhani 2007 Tanzania 150 Infectious
disease clinic
63 41 (19–69) Unknown patient 100, .2 days
without dose
84
Sarna 2008 India 310 Public and
private out-
patient clinic
16 36 (23–70) 96 patient $90, no. Doses
taken/no. prescribed
in past 4 days
84
Silva 2009 Brazil 412 Clinics at
referral hospital
21.8 36 (17–67) Unknown patient $90, no. Doses
taken/no. prescribed
in past 5 days
74.3
Stout 2004 Costa Rica 88 Social security
hospital
15 38.2 (18–79) 87 patient 100, no. Doses
taken/no. prescribed
past 3 days
85
Uzochukwu 2009 Nigeria 174 Teaching
hospital
37.5 34.6 (7.2) 95.6 patient 100, miss at least 1
dose in past 30 days
25
Wang 2007 China 181 Clinic 59.7 47.8 (11.3) 100 patient $95, no. Doses taken/
no. Doses prescribed
past 3 days
81.8
Weiser 2003 Botswana 109 Private clinic 50 Not
available
97.3 patient or
clinician
$95, previous year
of missing , 1 dose
in 10day period or
1 dose/week
54
Williams 2007 West Indies 96 Clinic 54.2 35.6 95 patient or
provider
$95, no. Doses
taken/no. prescribed
in past 7 days
87.7-patient,
87.0-provider
Abstracts
Dahab 2006 South Africa 69 Workplace ART
programme
1% 43.1 Unknown patient ,1 log drop in viral
load at 6 weeks after
treatment start
86
Shah 2006 India 279 Private clinic 27 Unknown patient .95, doses missed in
past 4 days
73
Warley 2006 Brazil 71 clinic 58 37.9 Unknown patient .95, doses missed in
past 4 days
70.4
Summary
(median, range)
51.5
(1–77)
37.9
(34.6–47.8)
95
(63.2–100)
73.6 (25–88)
doi:10.1371/journal.pone.0018948.t003
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considered an important determinant of self-efficacy which
previously has been positively associated with adherence to
ARVs [34,55].
Financial capital was one key factor impacting on adherence to
ARVs and the only type of capital which demonstrated a
significant association with adherence. The inability to afford
medication was one of the most frequently reported reasons for
non-adherence both in included studies [27,28,35,39,41] as well as
in others [56–58]. While access to free ARVs was associated with
non-adherence in one study [36], individuals receiving free
treatment may be more likely to be highly impoverished and
facing numerous obstacles (e.g., lack of food, shelter) which impact
on their ability to adhere [59]. Importantly, user fees and charges
for treatment are widespread in resource-poor settings [39]
although it has been suggested that optimal levels of adherence
can be achieved with access to subsidized ARVs [41,45]. A 2005
meta-analysis focused on ARV programmes in resource-poor
settings reported that, in fact, when medications were provided
free-of-charge, there was a higher probability of achieving
adherence and undetectable viral loads compared to situations
where patients were required to pay for treatment [18].
Even in the context of free drugs however, the cost of
transportation to obtain ARVs can still remain a barrier to
adherence. Research from sub-Saharan Africa has demonstrated
that patients often have to choose between using their limited
income on paying for transportation to the clinic versus being
able to adequately feed their families [60]. As a result, individuals
may miss their scheduled clinic appointments and thus not
receive their ARVs at the regular time intervals critical for
optimal adherence [38,61]. Therefore, increasing access to
affordable transportation as well as expanding the number and
location of ARV clinics may help to facilitate HIV treatment
adherence [38,62].
Findings related to food-related restrictions i.e. inability to take
medications on an empty stomach, and greater adherence when
eating well, were also associated with adherence in two studies.
Food insecurity has been well-documented in Africa and has been
linked with decreased adherence to ARVs and poor clinical
outcomes [61,63–65]. Medication-related food restrictions place
an additional burden on patients, in many ways, increasing the
complexity of the treatment regimen itself [62,66]. The perception
that ARVs need to be taken with food may lead to non-adherence
[40,42,67,68] suggesting that access to adequate food via self-
production or, at the very least, food supplements, bolsters human
capital, recognizing that taking pills on an empty stomach may
lead to gastrointestinal upset.
Social stability and social capital have both been associated with
medication adherence in various settings [69–73]. Importantly,
social support can take the form of direct reminders, financial help,
and emotional backing [71]. Qualitative research from South
Africa suggests that treatment supporters (i.e., clinic buddies) are a
valuable aid in promoting adherence [74]. As identified in this
review, social factors such marital status and having children can
impact on adherence. The desire to be alive and be able to support
their families and see their children grow up may be a strong
motivator for patients to adhere [39,69,71,75]. However,
disclosure to one’s sexual partner has been recognized as a double
edged sword [74]- it has the potential to yield much needed social
support [35] but may also result in stigmatization, discrimination,
and potentially abandonment [74,76,77]. This may partly explain
why adherence was higher for single individuals in one study [28].
Issues of stigma and discrimination related to HIV/AIDS remain
a real concern in many settings [78] and may lead to social
isolation, limit sources of social capital, and undermine relation-
ships that are essential for survival [70,78]. Further research in this
area is still needed to help elucidate the type and nature of social
capital that impacts on adherence across settings.
Table 4. Characteristics of included longitudinal papers [n=3, (43–45)] and conference abstracts [n=3, (49–51)].
Author Year Country N Setting
Female
(%)
Median
Age, y
Response
Rate
Follow-up
(FU) Assessor
Adherence, %
threshold for
measurement
Adherence
Proportion
(%)
Bonolo 2005 Brazil 306 Public
referral
hospital
35 35 73.4% Median
overall FU
time: 247 days
patient $95%, number
doses taken in
past 3 days
cumulative:
36.9%
Erah 2008 Nigeria 102 HIV
treatment
centre
64 mean:
36.3 (7.9)
81.6 Unknown patient $95%, number
doses taken in
past 30 d
58.1
Orrell 2003 South
Africa
289 University
HIV clinic
43 33.4 (8.7) 96.2 87.5% after
4 wk; 83.7%
after 48 wk
pharmacy
refill and
pill count
$90, medication
dispensed minus
pills returned/no.
Pills prescribed
over 48 weeks
63
Abstracts
Abah 2006 Nigeria 130 Teaching
hospital
N/A N/A N/A N/A patient and
pharmacy
$95, % of doses
prescribed over
6 month period
85.1
Darder 2004 South
Africa
192 Clinic N/A N/A N/A N/A patient $95, % of doses 88
Sidle 2007 Kenya 7381 clinics patient 100 77
Summary
(median,
range)
43 (35–64) 35 (33.4–
36.3)
81.6 (73–
96.2)
N/A: Not Available.
doi:10.1371/journal.pone.0018948.t004
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Limitations in our review reflect the quality and nature of
included studies. While our search was extensive and we did seek
clarification from various study authors, it is possible we missed
unpublished studies measuring the association between relevant
livelihood factors and adherence. There is no gold standard for
measuring adherence -patient recall and pill count, both
commonly used, have inherent biases in their use [79–81]. For
example, there is a tendency for self-reported adherence to be
positively skewed (i.e., patients overestimating adherence levels)
increasing the risk of patient misclassification [79]. While reporting
bias, specifically social desirability bias, may have a profound
impact here, other influences may include question misinterpre-
tation and issues of recall [82]. Additionally, the lack of
methodological standards makes assessments and comparisons
between levels of adherence difficult. As such there remains the
need for validation of adherence monitoring tools capable of
measuring real-time behaviour of patients in various settings [81].
While numerous livelihood factors were examined, few were
measured using standardized or validated instruments for
particular constructs, again reflecting the dearth of research
conducted in this area to-date and perhaps the lack of experience
among clinical investigators with use of standard measures more
out of social science traditions.
Unmeasured or unidentified features of included studies may
also have a large impact on either apparent or real adherence [15].
Detailed population descriptions (e.g., education level) and the
regional and political conditions under which a study was
conducted would assist interpretation of future studies in this
field. For example, patients with access to private or non-
governmental health services may have additional benefits
including better access to laboratory equipment and testing [43]
which may ultimately affect treatment outcomes. Furthermore,
patients in care and on ARVs may differ meaningfully from
patients who either lack access to ARVs or who refused treatment.
The experiences of livelihood insecurity for these individuals may,
in part, explain why they are not or did not remain in care, but
such populations were rarely included. Finally, the majority of
included studies were cross-sectional in study design, limiting the
ability to establish temporal causality (i.e., livelihood to adherence)
validly.
Conclusions
We found only one significant association that was consistent
across settings. We demonstrated a positive association between
financial capital and adherence whereas no statistically significant
relationship was found for human or social capital and adherence.
Importantly, the included studies reflect a range of experiences in
the association between various livelihood factors and adherence
to ARVs. This heterogeneity and diversity can also be considered
an important strength of this review. More longitudinal studies
that can effectively measure and monitor the dynamic interactions
between livelihood security and adherence across settings are
needed. Linked to these could be additional qualitative work able
to explore the lives and treatment challenges of PLWHA [83].
Both study designs are essential for understanding adherence, the
way adherence changes over time, and the reasons for non-
adherence. Through their incorporation in structural policies or
programs, findings from such research can contribute to improved
patient outcomes [84]. Furthermore, clinicians and other health
providers can actively work with their patients and help them to
prioritize adherence while addressing potential obstacles to care
[84,85]. As many of these obstacles and challenges lie beyond the
control of the individual patient, addressing adherence in low- and
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lowering user fees and patient costs, bringing care closer to the
patients, and implementing community-based livelihood develop-
ment strategies.
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